$TAC

TRANSALTA CORP

1
0
0

No SEC Form 4 filings for $TAC in the last 30 days.

Med

Across the Nutraverse: Probiotic foods in China, Akkermansia I.P., IM8’s $1bn financing deal

SAMR has drafted new China rules for probiotic health foods, open for consultation until Aug 24, 2026, including higher minimum CFU at shelf life and required strain details for traceability and quality. The Akkermansia Company received a new US patent covering marketing substantially purified Akkermansia for metabolic disorders, including live and pasteurized forms. IM8 secured $1bn growth financing from General Catalyst’s CVF to expand internationally.

State confirms TransAlta natural gas transition, requests public comment

Washington state’s Department of Ecology said it reached an agreement with TransAlta to transition the TransAlta Centralia plant from coal to natural gas. The plant is expected to start natural gas generation by 2028 and stop burning fossil fuels by 2044. TransAlta will invest $7 million to $21 million annually in Lewis and Thurston counties. Public comments run until Sept. 6.

TAC sentiment & insider activity

Over the past 7 days, alphai's AI scored 1 news story mentioning TAC (TRANSALTA CORP). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent TAC coverage spans financial news, regulation and earnings.

What's driving TAC

  • New, broader US patent protection can strengthen TAC’s IP moat and improve licensing or commercialization optionality for metabolic-disorder indications.

    nutraingredients.com · Aug 3, 2026

  • Regulatory approval and mitigation funding requirements reduce transition uncertainty and can shift near-term cash needs and operating assumptions for the Centralia asset.

    chronline.com · Aug 1, 2026

  • Results show weaker profitability and cash flow versus Q2 2025, but management highlights hedging and credits offsetting merchant gas carbon costs.

    thestarphoenix.com · Jul 31, 2026

  • FERC cost-recovery proceedings could determine whether TAC recoups standby costs, affecting near-term cash flows and regulatory risk perception.

    yakimaherald.com · Jun 27, 2026

  • Analyst initiation/renewal plus a fresh capital-raise/acquisition context can shift near-term sentiment and positioning, but it’s not a new fundamental print from the company itself.

    finance.yahoo.com · Jun 26, 2026

alphai scores every news story that mentions TAC with an AI model for sentiment and relevance, and aggregates insider trades from TRANSALTA CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TAC

Score

Across the Nutraverse: Probiotic foods in China, Akkermansia I.P., IM8’s $1bn financing deal

SAMR has drafted new China rules for probiotic health foods, open for consultation until Aug 24, 2026, including higher minimum CFU at shelf life and required strain details for traceability and quality. The Akkermansia Company received a new US patent covering marketing substantially purified Akkermansia for metabolic disorders, including live and pasteurized forms. IM8 secured $1bn growth financing from General Catalyst’s CVF to expand internationally.

State confirms TransAlta natural gas transition, requests public comment

Washington state’s Department of Ecology said it reached an agreement with TransAlta to transition the TransAlta Centralia plant from coal to natural gas. The plant is expected to start natural gas generation by 2028 and stop burning fossil fuels by 2044. TransAlta will invest $7 million to $21 million annually in Lewis and Thurston counties. Public comments run until Sept. 6.

The tab to keep a Northwest coal plant on standby keeps rising. Who will pay?

Utilities in the Pacific Northwest are contesting TransAlta’s request to recover costs for keeping its Centralia, Washington coal plant on standby under renewed Trump-era DOE emergency orders. TransAlta says its first April 30 invoice was nearly $20 million and estimates $23 million for repairs if standby extends into Q3–Q4 2026. FERC is reviewing opposition from utilities and grid operators.

TransAlta (TAC) Earns Buy Rating From TD Securities Despite Recent Share Weakness

TD Securities resumed coverage of TransAlta (NYSE:TAC) on June 10 with a Buy rating and a C$26 price target after the company completed a bought-deal equity offering. The firm cited a 13% stock pullback tied to concerns about TransAlta’s planned $1B acquisition of two Denver-area gas peakers from Blackstone. The assets total 318 MW, with expected ~$80M annual adjusted core profit and ~$33M free cash flow.

Barlow’s Research Roundup: These stocks are the big winners from Canada’s new nuclear energy plan

The Globe and Mail’s Scott Barlow roundup cites RBC Capital Markets’ Maurice Choy saying Canada’s new nuclear strategy could benefit TC Energy and Hydro One in Ontario and Capital Power, TransAlta and Canadian Utilities in Alberta, with Brookfield Renewables noted for global exposure. Scotiabank’s Hugo Ste-Marie flags a weak loonie at US$0.706 and widening rate differentials. BofA says copper supply constraints likely keep markets structurally tight.

$TACMedAI 8/10

TransAlta (NYSE:TAC) Stock Price Passes Above 200

TransAlta (NYSE:TAC) shares rose above their 200-day moving average on Monday, trading up to $13.82 and last at $13.5650. The 200-day average is $13.23. The article cites analyst actions including RBC and CIBC reiterating “outperform” and TD Securities “buy,” with MarketBeat showing a $21.33 consensus target. It also notes May 6 quarterly EPS of $0.04 vs $0.01 expected and a $0.07 quarterly dividend payable July 1.

$TACMed

TransAlta to pay six preferred-share dividends, topped by C$0.43088

TransAlta Corporation has declared quarterly dividends for six series of its cumulative redeemable rate reset first preferred shares, payable on June 30, 2026, to shareholders of record on June 1, 2026. The per-share dividends range from C$0.26309 to C$0.43088, with Series B and Series D having floating rates that reset quarterly. The highest dividend rate of 6.894% (C$0.43088 per share) is for Series E.

TAC Financials: Revenue Breakdown, Margins & Competitor Comparison

TransAlta Corp (TAC) generates most of its revenue from Gas, accounting for 53.0% of total sales, followed by Energy Transition and Hydro. The company displays a gross margin of 17.71%, with operating and net margins in negative territory, and a Return on Equity of -30.13%. TAC, with a market capitalization of $3.77B, competes with companies like TXNM and KEN, and its gross margin is significantly lower than TXNM's but comparable to KEN's.

Related tickers